Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy-Reference-Cited by-同舟云学术

Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy

Published:2017-10 Issue:4-5 Volume:3 Page:470-479
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Abrahamsson Per-Anders,Boccon-Gibod Laurent,Morote Juan,de Jong Igle Jan,Malmberg Anders,Neijber Anders,Albers Peter

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer;Spry;Eur J Cancer,2006

2. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials;Sciarra;Eur Urol,2013

3. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer;Abrahamsson;Eur Urol,2010

4. Mottet N, Belmunt J, Briers E, et al. Guidelines on prostate cancer, 2015. European Association of Urology. http://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf

5. Prostate cancer, version 1.2014;Mohler;J Natl Compr Canc Netw,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer;Expert Opinion on Pharmacotherapy;2021-06-30

2. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate;American Journal of Clinical Oncology;2020-09-23

3. Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China;Asian Journal of Urology;2020-07